LAGOS – Urbanisation, environmental changes, and lifestyle modifications in low- and middle-income countries are driving a sharp rise in allergy rates across Africa, while barriers to accessing ...

GoodRx reports that choosing the right asthma inhaler depends on symptom severity and frequency, with options for quick ...

Severe childhood asthma remains a major challenge in low- and middle-income countries. Find out more about treatment gaps and ...

How to step up asthma treatment in a child who can't use a dry powder inhaler (DPI) licensed for Maintenance and Reliever Therapy (MART) ...

Add Yahoo as a preferred source to see more of our stories on Google. A major pharmaceutical company ended price hikes and monopoly protection over a life-saving asthma inhaler following two years of ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...

Please provide your email address to receive an email when new articles are posted on . Single maintenance and reliever therapy (SMART) had a lower total annual asthma management cost vs. traditional ...

Asthma may not be driven by the molecules scientists have blamed for decades. Researchers have identified “pseudo leukotrienes,” inflammation-triggering compounds formed by uncontrolled free-radical ...

U.S. Rep. Kweisi Mfume (D-Md.-7) and Sen. Angela Alsobrooks (D-Md.) are teaming up on a new push to provide relief to those suffering from chronic lung conditions. Both members of Congress have put ...

After receiving his degree in Journalism & Media Communications from CSU in 2019, Erik began building his career in online media, and found his dream job when he joined Game Rant as a staff writer.

Please provide your email address to receive an email when new articles are posted on . The single inhaler includes an inhaled corticosteroid, a long-acting beta-agonist and an anticholinergic. The ...

Findings showed BDP/FF/G improved predose FEV1 and reduced the rate of moderate to severe exacerbations compared with BDP/FF. The Food and Drug Administration (FDA) has accepted for review the New ...